Navigation Links
Chemo Patients Pose Potential Public Health Risk
Date:9/19/2013

NEWPORT, R.I., Sept. 19, 2013 /PRNewswire-iReach/ -- In its second edition of "Safe Management of Wastes from Health-Care Activities," released in August, the World Health Organization (WHO) singled out contact with residual amounts of chemotherapy drugs as a significant risk requiring collection, containment and proper disposal in order to avoid exposure "through contact with body fluids and secretions [urine, feces and vomit] of patients undergoing chemotherapy."

Genotoxic/cytotoxic compounds, most commonly found in chemotherapy drugs, work by either mutating or killing cells. Unlike poisons, which can be safe when exposure is limited to tiny amounts, genotoxins/cytotoxins act more like "chemical germs," where even minimal exposure can cause a devastating chain reaction. The risk from contact to an otherwise healthy person is especially heightened when there is a significant amount of cell development happening — for example, among children and women of childbearing age.

According to the WHO report, any wastes produced by these patients within 48 hours of drug administration, and in some cases for up to a week, should be considered genotoxic.

Despite the otherwise well-regulated and well-managed handling of dangerous medical waste, chemotherapy patients treated with any of more than two dozen different chemotherapy drugs who return home after outpatient treatment can inadvertently but easily expose others to genotoxic contamination through seemingly benign occurrences such as urine splashed on a bathroom floor, clean up after an episode of vomiting, or the handling of bed sheets or a bedpan for a patient unable to use a bathroom.

The WHO report address what many in the field of chemotherapy-based treatment have long acknowledged as a dangerous "blind spot."
The human body can only destroy a portion of these genotoxic drugs. The rest passes out of the patient in urine, feces, vomit, or even sweat. The waste will still have enough dangerous drug to kill developing cells and/or cause mutations in vulnerable members of our population, especially fetuses and babies.

The WHO has done a great public service by stepping up and publicly declaring what many of us in the field have long known — this is a serious risk.

WHO core principles "require that everyone associated with financing and supporting health-care activities should provide for the costs of managing health-care waste. This is the duty of care. Manufactures also share a responsibility to take waste management into account in the development and sale of their products and services."

The WHO goes on to identify those who have a special responsibility to ensure safe collection, containment and disposal of these wastes, placing much of that responsibility with the chief pharmacist. "The chief pharmacist also has the special responsibility of ensuring that genotoxic products are used safely, and that genotoxic waste is managed safely," according to the WHO.

Jim Mullowney is the founder and CEO of Newport-based Pharma-Cycle Inc

Media Contact: Jim Mullowney, Pharma-Cycle, Inc., 617-755-0883, jmullowney@pharma-cycle.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Pharma-Cycle, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Big Pharma to Come Together at ChemOutsourcing 2013 in Long Branch, New Jersey, Sept 16-19
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. ChemOutsourcing Announces 100 CMO and CRO Exhibitors for September 2013 Show in Long Branch, New Jersey
4. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
5. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
6. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
7. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
8. Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
9. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
10. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... Ca (PRWEB) , ... January 19, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, announces the ... offers users a quick and easy portal to research breakthroughs and trending news, ...
(Date:1/19/2017)... Los Angeles, CA (PRWEB) , ... January 19, 2017 , ... ... their listing of plastic surgery procedures in order to make it easier for their ... the part of the body they impact as well as the techniques used on ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at ... his internship in internal medicine at the Emory University and dermatology training at ...
(Date:1/19/2017)... California (PRWEB) , ... January 19, 2017 , ... ... hands of a doctor who administered fillers that resulted in severe facial disfiguration. ... case was taken on by doctors at UCLA Medical Center, who removed the ...
Breaking Medicine News(10 mins):